

[Handwritten signature]
8/1/18

Daniel J. Lenihan, MD, FACC


PERSONAL DATA:

DATE & PLACE OF BIRTH: May 13, 1962; Cleveland, OH
Citizenship: USA

OFFICE ADDRESS: Washington University School of Medicine
660 S. Euclid Ave.
Campus Box 8086
St. Louis, MO 63110

OFFICE PHONE NO.: cell phone (615) 294-3631

OFFICE FAX NO.: (314) 454-5550



PRESENT POSITION (9.1.17): Professor of Medicine,
Director of the Cardio-Oncology Center of Excellence

EDUCATION:

8/1980-6/1984 B.A.; Chemistry & Zoology
University of Tennessee, Knoxville, TN
8/1984-6/1988 M.D.
University of Tennessee Health Science Center, Memphis, TN
7/1988-6/1991 Residency, Internal Medicine
Wright-Patterson Air Force Base, Dayton, OH
7/1992-7/1995 Fellowship, Cardiology
University of Cincinnati, Cincinnati, OH

ACADEMIC POSITIONS:

7/1996-7/1998 Assistant Professor, Department of Internal Medicine, Division of Cardiology,
Uniformed Services University for Health Sciences, Bethesda, MD
7/1997-7/1998 Assistant Professor, Department of Internal Medicine, Wright State University,
Dayton, OH
9/1998-12/2000 Assistant Professor, Division of Cardiology, University of Texas Medical
Branch at Galveston, Galveston, TX
12/2000-7/2001 Associate Professor, Division of Cardiology, University of North Carolina at
Chapel Hill, Chapel Hill, NC
7/2003-8/2008 Associate Professor, Department of Cardiology, The University of Texas
M. D. Anderson Cancer Center, Houston, TX
8/2008-8/2009 Professor, Department of Cardiology, Division of Internal Medicine,
The University of Texas, M. D. Anderson Cancer Center, Houston, TX
9/2009-Present Professor, Division of Cardiovascular Medicine, Department of Medicine,
Vanderbilt University, Nashville, TN

ADMINISTRATIVE APPOINTMENTS/EMPLOYMENT:

7/1995-6/1998 Director, Coronary Care Unit, Pacemaker Services and Phase II Cardiopulmonary
Education, Wright-Patterson Air Force Base Medical Center, Dayton, OH
7/1998-12/2000 Co-Director, Heart Failure Program and Director of Cardiac Rehabilitation,
Division of Cardiology, University of Texas Medical Branch at Galveston,
Galveston, TX
12/2000-7/2001 Associate Director, Heart Failure Program, Division of Cardiology, The University
of North Carolina at Chapel Hill, Chapel Hill, NC
7/2001-7/2003 Director, Heart Failure Program, Cardiovascular Specialists of Texas,
Texas City, TX

1/2004-8/2009	Director of Clinical Research, Department of Cardiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
7/2006-6/2008	Associate Director, Heart and Lung Center, Department of Cardiology, Division of Internal Medicine, The University of Texas M.D., Anderson Cancer Center, Houston, TX
7/2008-8/2009	Director, Heart and Lung Center, Department of Cardiology, Division of Internal Medicine, The University of Texas M.D., Anderson Cancer Center, Houston, TX
9/2009-8/2017	Director of Clinical Research, Division of Cardiovascular Medicine, Program Director, Advanced Heart Failure/Transplant Fellowship Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

PROFESSIONAL ACTIVITIES:

Institutional Service

2003 – 2006	Clinical Trial Finance Committee
2003 – 2007	CPR Committee, Member
2003 – 2006	Clinical Research Committee, Member
2003 – 2008	Heart Success Program, Medical Director
2004 – 2008	Adult Cardiovascular Drugs Subcommittee, Pharmacy and Therapeutic Committee
2004 – 2009	Cardiology Department Clinical Research Committee, Chairman
2004 – 2006	Division of Internal Medicine Research Committee, Co-Director
2005	Graduate of Faculty Leadership Academy, The Discovery Group V
2005 – 2009	Cardiology Research Database, Director
2005 – 2006	Cardiology Rotation Program, Program Coordinator
2005 – 2006	Graduate Medical Education Committee, Member
2006 – 2009	Institutional Review Board II, Associate Member
2010 – Present	Human Subject Protection Program, Member
2012 – Present	Program Director: Advanced Heart Failure/Transplant Fellowship

LICENSURE AND CERTIFICATION:

7/1990-9/1998	Ohio State Physician's License (Inactive)
9/1991-11/2013	Board Certification, Internal Medicine; Recertification: 11/2003
9/1995-12/2025	Board Certification, Cardiology; Recertification: 11/2003, 10/2015
8/1998-11/2018	Texas Medical License
1/2000-10/2010	Board Certification, Nuclear Cardiology Board
12/2000-5/2018	North Carolina State License
1/2007-1/2010	Vascular Interpretation Certification (ARDMS)
9/2009-5/2018	Tennessee State License
10/2012-12/2022	Board Certification, Advanced Heart Failure/Transplant
9/2017-	Missouri State License

MILITARY SERVICE:

6/1983-6/1988	United States Air Force Reserve, HPSP Scholarship
7/1988-6/1992	United States Air Force, MC, Captain
7/1995-7/1998	United States Air Force, MC, Major

HONORS AND AWARDS:

1980	College Scholars Program, University of Tennessee
1983	Department of Energy, National Research Grant, Oak Ridge Associated Universities
1984	Health Professions Scholarship, United States Air Force
1984	Outstanding Scholar-Athlete Award, University of Tennessee
1992	Wyeth-Ayerst Fellow Reporter Award, American Heart Association
1994	Syntex Scholarship Award, American College of Cardiology
1995	Cardiovascular Meeting Grant Award, ACC/Genentech

1996 Staff of the Year Award, Wright Patterson Air Force Base
2008 Top Doctors, Castle Connolly
2013 Enrique Lopez Award for Innovative and Humanitarian Achievement

EDITORIAL & REVIEW ACTIVITIES:

Service on Editorial Board(s)

2001– 2015 Section Editor, American Journal of Medical Sciences
2009– 2010 Editor, Cardiovascular Research and Practice
2011 – Present Editorial Board, Journal of Cardiac Failure
2012-present Editorial Board, OnCOreview
2014-present Editorial Board, Cardio-Oncology
2017-present Editorial Board, Circulation Heart Failure

Journal Reviewer

1998 – Present Journal Reviewer, American Journal of Medical Sciences
2003 – Present Journal Reviewer, Circulation
2003 – Present Journal Reviewer, Journal of Cardiac Failure
2005 – Present Journal Reviewer, American Heart Journal
2005 – Present Journal Reviewer, Clinical Cardiology
2005 – Present Journal Reviewer, Journal of the American College of Cardiology
2005 – Present Journal Reviewer, Texas Heart Institute Journal
2006 – Present Journal Reviewer, Annals of Internal Medicine
2007 – Present Journal Reviewer, Journal of Clinical Oncology
2008 – Present Journal Reviewer, Clinical Cancer Research
2008 – Present Journal Reviewer, Journal American Heart Association
2009 – Present Journal Reviewer, European Heart Journal
2009 – Present Journal Reviewer, The Oncologist
2009 – Present Journal Reviewer, Annals of Oncology
2010 – Present Journal Reviewer, JACC Heart Failure

Other Editorial and Review Activities

2009 – Present Founding Member, International CardiOncology Society
2009 Guest Editor, Progress in Cardiovascular Disease
2010 Guest Editor, Heart Failure Clinics
2010 – 2012 NIH Heart Failure Clinical Trial Study Section
2014 Guest Editor, Future Cardiology
2015 Guest Editor, Future Oncology
2016 Section Editor: Encyclopedia of CV Disease

PROFESSIONAL ORGANIZATIONS:

National and International

1995-2000 Society of Air Force Physicians
1997-Present American College of Cardiology, Fellow
1999-Present Heart Failure Society of America
2000-Present American Heart Association Council on Clinical Cardiology
2007-Present American Society of Clinical Oncology
2009-2010 HFSA Guidelines Sub-Committee: Development of Guidelines for Cardiac Toxicity and Complications of Cancer Therapy
2009-2010 NIH: Combined Toxicity Criteria-Adverse Events, Version 4 (CTCAE) Cardiac and Vascular Subcommittee
2009-Present International Cardio-Oncology Society, President
2011-2015 Cardiac Safety Research Consortium
2011-2015 Southern Society of Clinical Investigation
2013-2016 Board member: Canadian Cardiac Oncology Network
2014-2015 ASCO Cardiac Dysfunction in Cancer Survivors Guideline Committee

2014-Present	Member, European Society of Cardiology (ESC)
2014-Present	NIH Cardiac Safety Community Subcommittee
2014-Present	ESC Cardiotoxicity Detection Subcommittee
2015-Present	ACC: Council on Cardio-Oncology

CONFERENCES & SYMPOSIUMS:

March, 2004	Program Director, University of Texas Medical School at Houston, Texas Medical Center Cardiology Board Review Series, Houston, TX
October, 2004	Moderator, Texas Heart Institute, Fourth Symposium on Congestive Heart Failure, Houston, TX
May, 2005	Co-Director, The University of Texas M.D. Anderson Cancer Center, Division of Internal Medicine Research Retreat, Houston, TX
August, 2005	Program Director, The University of Texas Medical School at Houston, Second Annual Texas Medical Center Cardiology Board Review, Houston, TX
September, 2005	Chair, The University of Texas M.D. Anderson Cancer Center, HFSA Cardiology and Oncology Partnership Advisory Board Meeting, Boca Raton, FL
May, 2006	Co-Director, The University of Texas M.D. Anderson Cancer Center, Division of Internal Medicine Research Retreat, Houston, TX
September, 2006	Chair, The University of Texas M.D. Anderson Cancer Center, Second Annual HFSA Cardiology and Oncology Partnership Advisory Board Meeting, Seattle, WA
February, 2007	Program Director, The University of Texas M.D. Anderson Cancer Center, Cardiology And Oncology Partnership: Bridging the Gaps to Improve Patient Outcomes, Houston, TX
June, 2007	Chair, The University of Texas M.D. Anderson Cancer Center, Cardiology and Oncology Partnership Meeting at ASCO, Chicago, IL
September, 2009	Chair, Cardiology and Oncology Partnership, Cardiology and Oncology Partnership: Cardioncology 2009, Milan, Italy
October, 2010	Chair, Cardiology and Oncology Partnership 4 th Annual International Symposium Nashville, TN
August, 2011	Program Director, First Annual Middle Tennessee Cardiovascular Disease Update: Standard and Emerging Diagnostic and Treatment Strategies, Murfreesboro, TN
October, 2011	Chair, International CardioOncology Society V Annual Meeting, Silver Springs, MD
November, 2011	Program Committee, Drug Information Association (DIA) Annual Meeting, Barcelona, Spain
August, 2012	Program Director, Second Annual Middle Tennessee Cardiovascular Disease Update: Standard and Emerging Diagnostic and Treatment Strategies, Murfreesboro, TN
September, 2012	Program Director, International CardioOncology Society VI Annual Meeting, Milan, Italy
December, 2013	Chair, International CardioOncology Society in conjunction with the Cardiac Safety Research Consortium (CSRC) Annual Meeting, Washington, DC
April, 2015	Lankenau Symposium, Philadelphia PA
June, 2015	International Symposium on Cardio-Oncology, Madrid, Spain
July, 2015	Faculty, Cardio-Oncology Mini-Symposia, FDA, Bethesda, MD
October, 2015	Co-Chair, Global Cardio-Oncology Summit, Nashville, TN
September, 2016	Co-Chair, Global Cardio-Oncology Summit, Vancouver, BC, Canada

TEACHING ACTIVITIES:

2003 – 2007	Instructor, ACLS, The University of Texas M.D. Anderson Cancer Center
2006	Atrial and Ventricular Pacemakers. The University of Texas M.D. Anderson Cancer Center
2006	Angina and Acute Myocardial Infarction, Baylor College of Medicine Physician Assistant Program

TRAINING:

2003 – 2006	Instructor, Acute Decompensated Heart Failure, The University of Texas M.D. Anderson Cancer Center
-------------	--

2003 – 2006	Instructor, Vascular Disease, The University of Texas M.D. Anderson Center
2003 – 2009	Instructor, Management of Cardiac Toxicity-Medical Oncology Fellowship
2012 – Present	Program Director: Advanced Heart Failure/Transplant Fellowship

DIRECT SUPERVISION:

2003 – 2009	Attending, Echocardiography Lab, UT Cardiology Fellows
2003 – 2009	Attending, Consult Service, UT Cardiology Fellows
2006 – 2007	Supervisor, Clinical Research Program, Undergraduate, Research Internship, Allied Health Students and Graduate Students, The University of Texas M.D. Anderson Cancer Center
2009 – Present	Heart Failure Service, Inpatient Step-down and ICU

Trainees

2006	Aisha Pinto, Research Internship, Undergraduate and Allied Health Student
2006 – 2007	Shalabh Chandra, Graduate Student, Clinical Research Program
2007	Abeshik Mehta, Graduate Student, Clinical Research Program
2010	Jesalyn Tate, Medical Student
2012	Nicholas Haglund MD, Heart Failure/Transplant Fellow
2013	Haree Vongooru, M.D., Heart Failure/Transplant Fellow
2014	Dmitry Abramov, M.D., Heart Failure/Transplant Fellow
2014	Sandip Zalawadiya, M.D., Heart Failure/Transplant Fellow
2015	Samuel Coffin, MD., Heart Failure/Transplant Fellow
2015	Jayant Raikhelker, MD., Heart Failure/Transplant Fellow
2016	Ugo Egolum, M.D., Heart Failure/Transplant Fellow
2016	Omair Ali, M.D., Heart Failure/Transplant Fellow
2017	Carlos Ruiz, MD and Gabriel Hernandez, MD HF/Transplant Fellows

RESEARCH PROGRAM:

Current Awards

None

Past Awards

2004-2009	Principal Investigator, Cardiology Research Database, The University of Texas M.D. Anderson Cancer Center
2007-2015	Principal Investigator, A multicenter study in Patients undergoing anthRacycline-based chemotherapy to assess the Effectiveness of using biomarkers to Detect and Identify Cardiotoxicity and describe Treatment (PREDICT), 2007-0914, NCI and Alere, Inc.
2009	Principal Investigator, Cardiology & Oncology Partnership Program, Lance Armstrong Foundation
2012	Principal Investigator, The Cardiovascular Effects of Sunitinib Therapy: Off-Target Changes in Cardiac Metabolism and Ventricular-Vascular Mechanics (CREST) Study
2014	PROTECT Study, Millenium. Prospective Observation of Cardiac Safety with Proteasome Inhibition
2015	St Jude Life Pulmonary Hypertension in Adult Survivors of Childhood Cancer
2015	Long Term Follow Up of Patients Treated with Neuregulin, a Phase 1 study

Protocols

2003-2005	Principal Investigator, A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Effects of Vasogen's Immune Modulation Therapy (IMT) on Mortality and Morbidity in Patients with Chronic Heart Failure (ACCLAIM), 2003-0674
2003-2006	Principal Investigator, Identification of Biologic and Physiologic Correlates of Anemia in Patients with Congestive Heart Failure (CHF), ID03-0259
2003	Principal Investigator, Phase IV, Open Labeled Study to Test the Effectiveness of Nesiritide in Reversing Pulmonary Hypertension, 2003-0562
2004-2005	Principal Investigator, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Tezosentan in Patients with Acute Heart Failure (VERITAS), 2004-0366
2004	Principal Investigator, A Pilot Study to Assess Change in Exercise Heart Rate as a Dosing Strategy for Beta Blocker Therapy in Patients with Heart Failure Due to Left Ventricular Systolic Dysfunction (TARGET HR), 2004-0013
2004	Principal Investigator, AWARE: Analysis of a New AT/AF Detection Algorithm in Patients with Atrial Arrhythmias, 2004-0920
2004	Principal Investigator, REMODEL: A Randomized, Double Blind, Multicenter, Study Evaluating the Effects of Eplerenone Versus Placebo on Ventricular Remodeling in Patients with Left Ventricular Systolic Dysfunction (EF < or = 35%) and Mild To Moderate Heart Failure, 2004-0433
2005	Principal Investigator, Atrial Fibrillation: Focus on Effective Clinical Treatment Strategies (AFFECTS) Registry, 2005-0507
2005	Principal Investigator, Early Detection of Cardiotoxicity During Chemotherapy Using Biomarkers, 2005-0293
2006-2009	Principal Investigator, Registry of AT/AF Episodes in the CRM Device Population: RATE Registry, 2006-0916
2007-2009	Principal Investigator, Phase 3, Active (Warfarin) Controlled, Rand., Dbl-Blind, Parallel-Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Pts with Nonvalvular Atrial Fibrillation, 2007-0049
2007-2009	Co-Principal Investigator, Take Heart: Exercise & Diet Intervention for Heart Failure in Cancer Survivors, 2007-0822
2008-2009	Principal Investigator, A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS) Subjects with Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Who are Medically Managed - The TRILOGY ACS Study (Protocol Number H7T-MC-TABY), 2007-0747, ELI LILLY
2009-Present	Principal Investigator, A Phase 1, Double-Blind, Placebo-Controlled Study of Single Ascending Doses of GGF2 in Patient with Left Ventricular Dysfunction and Symptomatic Heart Failure. Acorda Therapeutics, 100847
2011-Present	Principal Investigator, Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF). St. Jude Medical, 101008

- 2011-Present Principal Investigator, Vanderbilt Heart and Vascular Institute Main Heart Registry, 090828
- 2011-Present Principal Investigator, Characterization of neuregulin-1, angiogenic growth factors and markers of inflammation in a cohort of patients with ischemic and non-ischemic cardiomyopathy, 100612
- 2012-2016 Principal Investigator (Site), The Cardiovascular Effects of Sunitinib Therapy: Off-Target Changes in Cardiac Metabolism and Ventricular-Vascular Mechanics CREST Study, University of Pennsylvania, 120113
- 2012-Present Site PI, ST Monitoring to Detect ACS Events in ICD Patients (Analyze ST). St. Jude Medical, 111447
- 2012-Present Principal Investigator (site), A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of IV Infusion Treatment with OmecamtivMecarbil Subjects with Left Ventricular Systolic Hospitalized for Acute Heart Failure – Atomic – AHF Study. Amgen, Inc., 120294
- 2014–Present PROTECT Study, Principal Investigator

THAOS Registry – Pfizer, Inc. (enrolled 21)
Transthyretin-Associated Amyloidosis Outcomes Survey (Thaos): A Global, Multi-Center, Longitudinal, Observational Survey of Patients with Documented Transthyretin (Ttr) Mutations Or Wild-Type Ttr Amyloidosis

ATTR-ACT - Pfizer, Inc. (enrolled 12)
A Multicenter, International, Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826) 20 mg or 80 mg in Comparison to Placebo in Subjects Diagnosed With Transthyretin Cardiomyopathy (TTR-CM)

ENDEAVOR – Alnylam Pharmaceuticals, Inc (enrolled 6)
ENDEAVOR (ALN-TTRSC-004) A Phase 3 Multicenter, Multinational, Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN-TTRSC in Patients with Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Tafamidis TTR-CM extension study – Pfizer, Inc (rollover patients – to begin Feb. 2017)
Protocol B3461045: A Phase 3 Multicenter, Randomized, Double-Blind, Extension Study to Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826) 20 mg or 80 mg in Subjects Diagnosed with Transthyretin Cardiomyopathy (TTR-CM)

PACE – Investigator Initiated (enrolled 132)
Predicting Cardiac Effects of Breast Cancer Therapy

PREDICT – Univ. of Texas – MD Anderson (enrolled 52)
A Multi-Center Study in Patients Undergoing Anthracycline-Based Chemotherapy to Assess the Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment

CREST – Univ. of Penn (enrolled 31)
The Cardiovascular Effects of Sunitinib Therapy: Off-Target Changes in Cardiac Metabolism and Ventricular-Vascular Mechanics

PROTECT – Investigator initiated – funding Millennium (enrollment 94)
Prospective Observation of Cardiac Safety with Proteasome Inhibition

MADIT-CHIC – Univ. of Rochester Medical Center (enrollment 5)
Multicenter Automatic Defibrillator Implantation Trial -Chemotherapy-Induced
Cardiomyopathy

Adapt Response – Medtronic (enrolled 21)
Primary Investigator-Adapt Response study; a prospective, randomized, controlled,
Interventional, single-blinded, multi-center post-market, global Cardiac Resynchronization
Therapy (CRT) in heart failure (HF) clinical study

Victoria (enrolled 3)- Primary Investigator (site) –Randomized Parallel-Group, Placebo-
Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial
of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects with heart Failure with
Reduced Ejection Fraction (HFrEF) – Vericiguat Global Study in Subjects With Heart Failure
With Reduced Ejection Fraction (VICTORIA)

PUBLICATIONS AND PRESENTATIONS:

Original Research Articles

1. Lee T, **Lenihan DJ**, Malone B, Roddy LL, Wasserman SI. Increased biosynthesis of platelet-activating factor in activated human eosinophils. *J Biol Chem*, 1984; 259:5526-30.
2. **Lenihan DJ**, Lee TC. Regulation of platelet activating factor synthesis: modulation of 1-alkyl-2-lyso-sn-glycero-3-phosphocholine:acetyl-CoA acetyltransferase by phosphorylation and dephosphorylation in rat spleen microsomes. *Biochem Biophys Res Commun*, 1984; 120:834-9.
3. **Lenihan DJ**, Greenberg N, Lee TC. Involvement of platelet activating factor in physiological stress in the lizard, *Anolis carolinensis*. *Comp Biochem Physiol C*, 1985; 81:81-6.
4. **Lenihan DJ**, Zeman HS, Collins GJ. Left main coronary artery aneurysm in association with severe atherosclerosis: a case report and review of the literature. *Cathet Cardiovasc Diagn*, 1991; 23:28-31.
5. **Lenihan DJ**, Coyne E, Feldman B, Black R, Collins G. Frequency of late potentials on signal-averaged electrocardiograms during thallium stress testing in coronary artery disease. *Am J Cardiol*, 1992; 70:432-5.
6. **Lenihan DJ**. Treatment of Peripheral Vascular Disease. *Resident and Staff Physician* 1992; Supp:37-41.
7. **Lenihan DJ**, Gerson MC, Hoit BD, Walsh RA. Mechanisms, diagnosis, and treatment of diastolic heart failure. *Am Heart J*, 1995; 130:153-66.
8. **Lenihan DJ**, Gerson MC, Dorn GW, 2nd, Hoit BD, Walsh RA. Effects of changes in atrioventricular gradient and contractility on left ventricular filling in human diastolic cardiac dysfunction. *Am Heart J*, 1996; 132:1179-88.
9. Ochoa AB, Wolfe M, Lewis P, **Lenihan DJ**. Ticlopidine-induced neutropenia mimicking sepsis early after intracoronary stent placement. *Clin Cardiol*, 1998; 21:304-7.
10. Ritchie ME, Hattemer C, **Lenihan D**. Ergonovine-testing-directed therapy and long-term outcome of sudden-death survivors with no apparent heart disease. *Cardiology*, 1998; 89:76-8.
11. **Lenihan DJ**, McGoron AJ, Gabel M, Walsh RA, Gerson MC. Reliability of technetium-99m Q12 and thallium-201 myocardial activity measurements after triphenyl tetrazolium chloride myocardial staining by perfusion. *Invest Radiol*, 1999; 34:276-81.
12. **Lenihan DJ**, Rosenbaum AF, Burwinkel P, Tseng CY, Bhat G, Wagoner L, Walsh RA, Gerson MC. Prediction of human transplantation arteriopathy and coronary events with lung/heart count ratios during intravenous dipyridamole thallium-201 imaging. *Am Heart J*, 1999; 137:942-8.
13. Abreo G, **Lenihan DJ**, Nguyen P, Runge MS. High-output heart failure resulting from a remote traumatic aorto-caval fistula: diagnosis by echocardiography. *Clin Cardiol*, 2000; 23:304-6.

14. **Lenihan DJ**, Uretsky BF. Nonpharmacologic treatment of heart failure in the elderly. *Clin Geriatr Med*, 2000; 16:477-88.
15. Chamoun AJ, Conti V, **Lenihan DJ**. Native valve infective endocarditis: what is the optimal timing for surgery? *Am J Med Sci*, 2000; 320:255-62.
16. Otero J, **Lenihan DJ**. The "normothermic" Osborn wave induced by severe hypercalcemia. *Tex Heart Inst J*, 2000; 27:316-7.
17. Cation LJ, **Lenihan DJ**, Gutierrez-Nunez JJ. Military graduate medical education in internal medicine: an outcomes study. *Mil Med*, 2001; 166:314-7.
18. Chamoun AJ, **Lenihan DJ**, McCulloch M, Ahmad M, Sheahan RG. Resynchronization therapy in dilated cardiomyopathy: confirmation of hemodynamic improvement with real-time three-dimensional echocardiography. *Circulation*, 2001; 103:E98-8.
19. Otero FJ, **Lenihan DJ**. Sarcoidosis-induced right ventricular hypertrophy and pulmonary hypertension: echocardiographic imaging. *Echocardiography*, 2001; 18:19-20.
20. **Lenihan DJ**, Osman A, Sriram V, Aitsebaomo J, Patterson C. Evidence for association of coronary sinus levels of hepatocyte growth factor and collateralization in human coronary disease. *Am J Physiol Heart Circ Physiol*, 2003; 284:H1507-12.
21. Patel P, **Lenihan DJ**. The current status of immune modulating therapy for myocarditis: a case of acute parvovirus myocarditis treated with intravenous immunoglobulin. *Am J Med Sci*, 2003; 326:369-74.
22. Giesler G, **Lenihan DJ**, Durand JB. The update on the rationale, use and selection of beta-blockers in heart failure. *Curr Opin Cardiol*, 2004; 19:250-3.
23. Yeh ET, Tong AT, **Lenihan DJ**, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. *Circulation*, 2004; 109:3122-31.
24. Stouffer GA, **Lenihan DJ**, Lerakis S, Agahtehrani A, Ahn J, Martin RP. Timing of aortic valve surgery in chronic aortic stenosis and regurgitation. *Am J Med Sci*, 2004; 327:348-51.
25. **Lenihan DJ**, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. *Blood*, 2004; 104:655-8.
26. Murtagh BM, **Lenihan DJ**, Smalling RW. Endovascular repair of abdominal aneurysms: Is this the method of choice? *Am J Med Sci*, 2005; 330:184-91.
27. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, **Lenihan DJ**. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. *J Clin Oncol*, 2005; 23:7820-6.
28. Guarneri V, **Lenihan DJ**, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. *J Clin Oncol*, 2006; 24:4107-15.
29. Fadol A, **Lenihan DJ**. A case study of acute decompensated heart failure: a practical review of current recommendations. *The Hospitalist*, 2006; 10(10):21-24.
30. Feng J, **Lenihan DJ**, Johnson MM, Karri V, Reddy CV. Cardiac sequelae in Brooklyn after the September 11 terrorist attacks. *Clin Cardiol*, 2006; 29:13-7.
31. Sarkiss MG, Yusuf SW, Warneke CL, Botz G, Lakkis N, Hirsch-Ginsburg C, Champion JC, Swafford J, Shaw AD, **Lenihan DJ**, Durand JB. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. *Cancer*, 2007; 109:621-7.
32. Burjonrappa SC, Tong AT, Xiao LC, Johnson MM, Yusuf SW, **Lenihan DJ**. Cancer Patients with Markedly Elevated B-Type Natriuretic Peptide May Not Have Volume Overload. *American Journal Clinical Oncology*, 2007; 30:3:287-93.
33. Yusuf SW, Troung M, **Lenihan DJ**. Air embolism in the right ventricle. *Internal Medicine Journal*, 2007; 37:660-1.
34. Yusuf SW, Durand J-B, **Lenihan DJ**. Wrap Beats. *Am J Med*, 2007; 120:417-9.
35. Ewer MS, **Lenihan DJ**, Khakoo AY. Sunitinib-related cardiotoxicity: an interdisciplinary issue. *Nature Clinical Practice Cardiovascular Medicine*, 2008; 5(7):364-5.
36. **Lenihan DJ**. Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork? *J Clin Oncol*, 2008; 26(32):5154-5.
37. Ewer MS, **Lenihan DJ**. Is trastuzumab associated with adverse cardiac effects in patients with breast cancer? *National Clinical Practice Oncology*, 2008; 5(4):192-3.
38. Ewer MS, **Lenihan DJ**. Left Ventricular Ejection Fraction and Cardiotoxicity: Is Our Ear Really to the Ground? *Journal of Clinical Oncology*, 2008; 26(8):1201-3.

39. Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, Trent J, Champion JC, Durand JB, **Lenihan DJ**. Heart failure associated with sunitinib malate, a multi-targeted receptor tyrosine kinase inhibitor. *Cancer*, 2008; 112(11):2500-8.
40. **Lenihan, DJ**, Esteve FJ. Multidisciplinary Strategy for Managing Cardiovascular Risks when Treating Patients with Early Breast Cancer. *The Oncologist*, 2008; 13(12):1224-34.
41. Fadol A, Mendoza T, Gning I, Kernicki J, Symes L, Cleveland CS, **Lenihan DJ**. Psychometric Testing of the MDASI-HF: A Symptom Assessment Instrument for Patients with Cancer and Concurrent Heart Failure. *Journal of Cardiac Failure*, 2008; 14(6):497-507.
42. Chandra S, **Lenihan DJ**, Wei W, Yusuf SW, Tong AT. Myocardial Perfusion Imaging and Cardiovascular Outcomes in a Cancer Population. *Texas Heart Institute Journal*, 2009; 36(3):205-13.
43. Yusuf SW, Durand JB, **Lenihan DJ**, Swafford J. Dextrocardia: An incidental finding. *Texas Heart Institute Journal*, 2009; 36(4):358-9.
44. Lamkin DM, Spitz DR, Shahzad MM, Zimmerman B, **Lenihan DJ**, Degeest K, Lubaroff DM, Shinn EH, Sood AK, Lutgendorf SK. Glucose as a prognostic factor in Ovarian Carcinoma. *Cancer*, 2009; 115(5):1021-7.
45. Allen LA, Felker GM, Mehra MR, Chiong JR, Dunlap SH, Ghali JK, **Lenihan DJ**, Oren RM, Wagoner LE, Schwartz TA, Adams KF Jr. Validation and Potential Mechanisms of Red Cell Distribution Width as a Prognostic Marker in Heart Failure. *J Cardiac Failure*, 2009; 16(3):230-8.
46. Yusuf SW, Gladish G, **Lenihan DJ**, Lei X, Durand JB, Swafford J, Daher IN. Computerized Tomographic Finding of Saddle Pulmonary Embolism is associated with High Mortality in Cancer Patients. *Intern Med J*, 2010; 40(4): 293-9.
47. Ho TQ, **Lenihan DJ**, Kantharia BK, Dougherty AH. Noncompacted Ventricular Myocardium: is syncope the only warning sign? *Am J Med Sci*, 2010; 339(5):497-500.
48. Vaklavas C, **Lenihan D**, Kurzrock R, Tsimberidou AM. Anti-vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What are the Important Clinical Markers to Target? *The Oncologist*, 2010; 15(2):130-41.
49. Trent JC, Patel SS, Zhang J, Araujo DM, Plana JC, **Lenihan DJ**, Fan D, Patel SR, Benjamin RS, Khakoo AY. Rare Incidence of Congestive Heart Failure in Gastrointestinal Stromal Tumor and other Sarcoma Patients Receiving Imatinib Mesylate. *Cancer*, 2010; 116(1):184-92.
50. Wells QS, **Lenihan DJ**. Reversibility of Left Ventricular Dysfunction Resulting from Chemotherapy: Can This Be Expected? *Prog Cardiovasc Dis*, 2010; 53(2):140-8 Review.
51. **Lenihan DJ**, Cardinale D, Cipolla CM. The Compelling Need for a Cardiology and Oncology Partnership and the Birth of the International CardioOncology Society. *Prog Cardiovasc Dis*, 2010; 53(2):88-93.
52. **Lenihan DJ**, Krone RJ. Management of cardiac disease in cancer patients. *Prog Cardiovasc Dis*, 2010; 53(2):79.
53. Sanon S, **Lenihan DJ**, Mouhayar E. Peripheral arterial ischemic events in cancer patients. *Vascular Medicine*, 2010; 16(2):119-30.
54. Basen-Engquist K, **Lenihan DJ**, Hughes DC, Harrison CA. Exercise Intervention for Cancer Survivors with Heart Failure: Two Case Reports. *J Exerc Sci Fit*, 2011; 9(1): 65-73.
55. **Lenihan DJ**. Cardiovascular Side Effects of Antiangiogenic Therapy. Targeting Tumor Angiogenesis. The Angiogenesis Foundation, 2011.
56. **Lenihan DJ**, Sawyer DB. Cardio-oncology Related to Heart Failure. *Heart Failure Clinics*, 2011; 7(3).
57. Geisberg CA, **Lenihan DJ**. Neuregulin in Heart Failure. Reverse translation from cancer cardiotoxicity to new heart failure therapy. *Herz*, 2011; 36: 306-10.
58. Subbiah I. M., **Lenihan DJ**, et al. "Cardiovascular toxicity profiles of vascular-disrupting agents." *The Oncologist*, 2011; 16(8):1120-30.
59. **Lenihan D**, Suter T, et al. "Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab." *Annals of oncology: official journal of the European Society for Medical Oncology / ESMO*, 2012; 23(3):791-800.
60. Young MN, Shoemaker MB, Kurtz EG, **Lenihan DJ**. "Heart Failure with Preserved Left Ventricular Function: Diagnostic and Therapeutic Challenges in Patients with Diastolic Heart Failure." *Am J Med Sci*, 2012; 344(5):399-405.
61. Steingart RM, Bakris GL, Chen HX, Chen MH, Force T, Ivy SP, Leier CV, Liu G, **Lenihan**

- D, Lindenfeld J, Maitland ML, Remick SC, Tang WH. Management of cardiac toxicity in pati receiving vascular endothelial growth factor signaling pathway inhibitors. *Am Heart J*, 2012; 163(2):156-63.
62. Lacouture ME, **Lenihan D**, Wu S. Anticancer therapy-induced adverse events: practicing damage control. *Expert Opin Drug Saf*, 2012;11 Suppl 1:S1-3.
63. Christian JB, Finkle JK, Ky B, Douglas PS, Gutstein DE, Hockings PD, Laine P, **Lenihan DJ**, Mason JW, Sager PT, Todaro TG, Hicks KA, Kane RC, Ko HS, Lindenfeld J, Michelson EL, Milligan J, Munley JY, Raichlen JS, Shahlaee A, Strnadova C, Ye B, Turner JR. Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction. *Am Heart J*, 2012; 164(6):846-55.
64. **Lenihan DJ**. Statins in Preparation for Chemotherapy: "Do these medications help your fitness for battle?" *J Am Coll Card*, 2012; 60(23): 2391-2.
65. **Lenihan DJ**. Progression of Heart Failure From AHA/ACC Stage A to Stage B or Even C: Can We All Agree We Should Try to Prevent This From Happening? *J Am Coll Card*, 2012; 60(24): 2513-4.
66. **Lenihan DJ**, Cardinale DM. Late Cardiac Effects of Cancer Treatment. *J Clin Onc*, 2012; 30(30): 3657-64.
67. Geisberg CA, Abdallah WM, da Silva M, Silverstein C, Smith HM, Abramson V, Mayer I, Means-Powell J, Freehardt D, White B, **Lenihan D**, Sawyer DB. Circulating Neuregulin during the Transition from Stage A to Stage B/C Heart Failure in a Breast Cancer Cohort. *J Card Fail*, 2013; 19(1):10-5.
68. Egolum UO, Stover DG, Anthony R, Wasserman AM, **Lenihan D**, Damp JB. Intracardiac thrombus: diagnosis, complications and management. *Am J Med Sci*, 2013; 345(5):391-5.
69. Yusuf SW, Negi SI, **Lenihan DJ**. Infiltrative cardiomyopathy and pericardial disease. *Semin Oncol*, 2013; 40(2):199-209.
70. Shinn EH, **Lenihan DJ**, Urbauer DL, Basen-Engquist KM, Valentine A, Palmero L, Woods ML, Patel P, Nick AM, Shahzad MM, Stone RL, Golden A, Atkinson E, Lutgendorf SK, Sood AK. Impact of cardiovascular comorbidity on ovarian cancer mortality. *Cancer Epidemiol Biomarkers Prev*, 2013; 11(22):2102-9.
71. **Lenihan DJ**, Kowey PR. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. *Oncologist*, 2013; 8(18):900-8.
72. Maltais S, Jaik NP, Feurer ID, Wigger MA, DiSalvo TG, Schlendorf KH, Ahmad RM, **Lenihan DJ**, Stulak JM, Keebler ME. Mechanical circulatory support and heart transplantation: donor and recipient factors influencing graft survival. *Ann Thorac Surg*, 2013; 4(96):1252-8.
73. **Lenihan DJ**, Oliva S, Chow EJ. Cardiac toxicity in cancer survivors. *Cardinale D. Cancer*, 2013; (119 Suppl 11):2131-42.
74. Cox ZL, Calcutt MW, Morrison TB, Akers WS, Davis MB, **Lenihan DJ**. Elevation of plasma milrinone concentrations in stage D heart failure associated with renal dysfunction. *J Cardiovasc Pharmacol Ther*, 2013; 5(18):433-8.
75. **Lenihan D** and Cardinale D. Reply to R. Steiner et al. *J. Clin Oncol*, 2013; 10(31):1380.
76. Bickford CL, Agarwal R, Urbauer DL, Durand JB, **Lenihan DJ**. Efficacy and Safety of Ibutilide for Chemical Cardioversion of Atrial Fibrillation and Atrial Flutter in Cancer Patients. *Am J Med Sci*, 2014; 347(4):277-81.
77. Lenneman CG, Abdallah WM, Smith HM, Abramson V, Mayer IA, Silverstein C, Silverstein C, Means-Powell J, Paranjape SY, **Lenihan D**, Sawyer DB, Raj SR. Sympathetic nervous system alterations with HER2+ antagonism: an early marker of cardiac dysfunction with breast cancer treatment? *Ecancermedalscience*, 2014; (8):446.
78. Kim DH, Tate J, Dresen WF, Papa FC Jr, Bloch KC, Kalams SA, Ellis CR, Baker MT, **Lenihan DJ**, Mendes LA. Cardiac implanted electronic device-related infective endocarditis: clinical features, management, and outcomes of 80 consecutive patients. *Pacing Clin Electrophysiol*, 2014; 8(37):978-85.
79. Haglund NA, Cox ZL, Lee JT, Song Y, Keebler ME, DiSalvo TG, Maltais S, **Lenihan DJ**, Wigger MA. Are peripherally inserted central catheters associated with increased risk of adverse events in status 1b patients awaiting transplantation on continuous intravenous milrinone? *J Card Fail*, 2014; 20(9):630-7.
80. Ewer M, Gianni L, Pane F, Sandri MT, Steiner RK, Wojnowski L, Yeh ET, Carver JR, Lipshultz SE, Minotti G, Armstrong GT, Cardinale D, Colan SD, Darby SC, Force TL, Kremer LC, **Lenihan DJ**, Sallan SE, Sawyer DB, Suter TM, Swain SM, van Leeuwen FE.

- Report on the international colloquium on cardio-oncology (Rome, 12-14 March 2014). *Ecancermedicalscience*, 2014; 12(50):2162-70.
81. Ewer MS, Suter TM, **Lenihan DJ**, Niculescu L, Breazna A, Demetri GD, Motzer RJ. Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. *Eur J Cancer*, 2014; 12(50):2162-70.
82. Haglund NA, Feurer ID, Ahmad RM, DiSalvo TG, **Lenihan DJ**, Keebler ME, Schlendorf KH, Stulak JM, Wigger MA, Maltais S. Institutional volume of heart transplantation with left ventricular assist device explantation influences graft survival. *J Heart Lung Transplant*, 2014; 9(33):931-6.
83. Cox ZL, **Lenihan DJ**. Loop Diuretic Resistance in Heart Failure: Resistance Etiology-Based Strategies to Restoring Diuretic Efficacy. *J Card Fail*, 2014; 20(8):611-22.
84. Hahn VS, **Lenihan DJ**, Ky B. Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. *J Am Heart Assoc*, 2014; 2(3):e000665.
85. **Lenihan DJ** and Kowey PR. In reply. *Oncologist*, 2014; 3(19):307.
86. Haglund NA, Schlendorf K, Keebler M, Gupta C, Maltais S, Ely EW, **Lenihan D**. Is a palpable pulse always restored during cardiopulmonary resuscitation in a patient with a left ventricular assist device? *Am J Med Sci*, 2014; 4(347):322-7.
87. **Lenihan DJ**. Reversibility of effectively treated chemotherapy-related heart failure: raising our awareness and a call to action for cardiology. *J Card Fail*, 2014; 3(20):159-60.
88. **Lenihan DJ**. Cardiac biomarkers, cardiotoxicity, and active collaboration: is this the final frontier or the wave we should catch? *J Am Coll Cardiol*, 2014; 8(63):817-8.
89. Pieske B, Butler J, Filippatos G, Lam C, Maggioni AP, Ponikowski P, Shah S, Solomon S, Kraigher-Krainer E, Samano ET, Scalise AV, Müller K, Roessig L, Gheorghiade M, SOCRATES Investigators and Coordinators. Rationale and design of the Soluble guanylate Cyclase stimulator in heart failure Studies (SOCRATES). *Eur J Heart Fail*, 2014; 16(9):1026-38.
90. Melloni C, **Lenihan DJ**. Balancing Cancer Treatment Efficacy with the Risk of Cardiotoxicity and Strategies for Cardioprotection in Adults. *Progr in Pediatric Card*, 2014; 36(1-2):61-3.
91. **Lenihan DJ**. Cardio-oncology: a tremendous opportunity to improve patient care. *Future Oncol*, 2014; 11(14):2007-10. doi: 10.2217/fon.15.99.
92. Grandin EW, Ky B, Cornell R F, Carver J, **Lenihan DJ**. Patterns of Cardiac Toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. *J Card Fail* 2015; 21(2):138-44.
93. Oki Y, Ewer MS, **Lenihan DJ**, Fisch MJ, Hagemester FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: An open label single arm phase II trial. *Clin Lymphoma Myeloma Leuk*, 2015; 15(3):152-8.
94. Coffin ST, Benton SM Jr., **Lenihan DJ**, Naftilan A, Mendes LA. Eosinophilic Myocarditis-An Unusual Cause of Left Ventricular Hypertrophy. *Am J. Med Sci*, 2015; 349(4):358-62.
95. Collins S, Storrow AB, Albert N, Butler J, Ezekowitz JA, Felker GM, Fermann GJ, Fonarow GC, Givertz MM, Hiestand B, Hollander J, Lanfear D, Levy PD, Pang PS, Peacock WF, Sawyer DB, Teerlink J, **Lenihan DJ**. Early Management of Patients with Acute Heart Failure: State of the Art and Future Directions: A Consensus Document from the SAEM / HFSA Acute Heart Failure Working Group. *J Card Fail*, 2015; 21(1): 27-43.
96. Stevens PL, **Lenihan DJ**. Cardiotoxicity due to Chemotherapy: the Role of Biomarkers. *Curr Cardiol Rep*, 2015; 17(7):603. doi:10.1007/s11886-015-0603-y.
97. Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, Ponikowski P, Shah SJ, Solomon SD, Kraigher-Krainer E, Samano ET, Müller K, Roessig L, Pieske B; SOCRATES-REDUCED Investigators and Coordinators. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. *JAMA*, 2015; 314(21):2251-62. doi: 10.1001/jama.2015.15734.
98. Dent S, Liu P, Brezden-Masley C, **Lenihan D**. Cancer and Cardiovascular Disease: The Complex Labyrinth. *J Oncol*, 2015; 2015:516450. doi: 10.1155/2015/516450. PMID: 2645724

99. Sulpher J, Mathur S, **Lenihan D**, Johnson C, Turek M, Law A, Stadnick E, Datillo F, Graham N, Dent SF. An International Survey of Health Care Providers Involved in the Management of Cancer Patients Exposed to Cardiotoxic Therapy. *J Oncol*, 2015; 2015:391845. doi: 10.1155/2015/391848. PMID 26300916
100. Clarke E, **Lenihan D**. Cardio-oncology: a new discipline in medicine to lead us into truly integrative care. *Future Cardiol*, 2015; 11(4):359-61. doi: 10.2217/fca.15.55. No abstract available. PMID 26268677
101. **Lenihan DJ**, Wescott G. Cardio-oncology: a tremendous opportunity to improve patient care. *Future Oncol*, 2015; 11(14):2007-10. doi: 10.2217/fon.15.99. PMID 26198827
102. Bloom MW, Hamo CE, Cardinale D, KY B, Nohria A, Baer L, Skopicki H, **Lenihan DJ**, Gheorghiade M, Lyon AR, Butler J. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging. *Circ Heart Fail*, 2016; 9(1):e002661. doi:10.1161/CIRCHEARTFAILURE.115.002661. PMID 26747861
103. Hamo CE, Bloom MW, Cardinale D, KY B, Nohria A, Baer L, Skopicki, H, **Lenihan DJ**, Gheorghiadi M, Lyon AR, Butler J. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions. *Circ Heart Fail*, 2016; 9(2):e002843. doi:10.1161/CIRCHEARTFAILURE.115.002843. PMID: 26839395
104. Shinn EH, Valentine A, Jethanandani A, Basen-Engquists K, Fellman B, Urbauer D, Atkinson E, Yusuf SW, **Lenihan D**, Woods ML, Kies MS, Sood, AK, Carmack C, Morrison WH, Gillenwater A, Sturgis EM, Garden AS. Depression and Oropharynx Cancer Outcome. *Psychosom Med*, 2016; 78(1):38-48. doi:10.1097/PSY.0000000000000256. PMID 26632757
105. Maurer MS, Hanna M, Dispenzieri A, Witteles R, Drachman B, Judge DP, **Lenihan DJ**, Gottlieb SS, Shah SJ, Steidley DE, Ventura H, Muralie S, Silver MA, Jacoby D, Fedson S, Hummel SL, Kristen AV, Damy T, Plante'-Bordeneuve V, Coelho T, Mundayat R, Suhr OB, Waddington Cruz M, Rapezzi C, THAOS Investigators. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). *J Am Coll Cardiol*, 2016; 2(68):161-72.
106. Collins SP, Levy PD, Martindale JL, Dunlap ME, Storrow AB, Pang PS, Albert NM, Felker GM, Fermann GJ, Fonarow GC, Givertz MM, Hollander JE, Lanfear DJ, **Lenihan DJ**, Lindenfeld JM, Frank Peacock W, Sawyer DB, Teerlink JR, Butler J. Clinical and Research Considerations for Patients with Hypertensive Acute Heart Failure A Consensus Statement from the Society for Academic Emergency and the Heart Failure Society of America Acute Heart Failure Working Group. *Acad Emerg Med*, 2016, 23(8): 922-31.
107. Bhatia N, **Lenihan D**, Sawyer DB, Lenneman CG. Getting the SCOOP-Survey of Cardiovascular Outcomes From Oncology Patients During Survivorship. *Am J Med Soc*, 2016; 6(351):570-5.
108. **Lenihan DJ**, Stevens PL, Massey M, Piana JC, Araujo DM, Fanale MA, Fayad LE, Fisch MJ, Yeh ET. The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study. *J Card Fail*. 2016; 6(22):433-8.
109. **Lenihan DJ**, Hartlage G, DeCara J, Blaes A, Finet JE, Lyon AR, Cornell RF, Moslehi J, Oliveira GH, Murtagh G, Fisch M, Zeevi G, Iakobishvili Z, Witteles R, Patel A, Harrison E, Fradley M, Curigliano G, Lenneman CG, Magalhaes A, Krone R, Porter C, Parasher S, Dent S, Douglas P, Carver J. Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty. *J Card Fail*, 2016; 6(22):465-71.
110. Li W, Cornell RF, **Lenihan D**, Slosky D, Jagasia M, Piazza G, Missehi J. Cardiovascular Complications of Novel Multiple Myeloma Treatments. *Circulation*, 2016; 9(133):908-12.
111. Curigliano G., Cardinale D, Dent S, Criscitiello C, Aseyev O. **Lenihan D**, Cipolla CM. Cardiotoxicity of anticancer treatments: Epidemiology, detection and management. *CA Cancer J Clin*, 2016; 4(66):309-25.
112. Zamorano JL, Lancellotti P, Muñoz DR, Aboyans V, Asteggiano R, Galderisi M, Habib G, **Lenihan DJ**, Lip GY, Lyon AR, Fernandez TL, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM. [2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. *Kardiol Pol*, 2016; 74(11):1193-233. doi:10.5603/KP.2016.0156. Polish. PMID: 27910076
113. Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC, Francis GS, **Lenihan D**, Lewis EF, McNamara DM, Pahl E, Vasan RS, Ramasubbu K, Rasmusson K, Towbin JA,

- Yancy C. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; and Council on Quality of Care and Outcomes Research. *Circulation*, 2016;134(23):e579-e646. Erratum in: *Circulation*, 2016; 13(23):e652. PMID:27832612
114. Swiger KJ, Friedman EA, Brittain EL, Tomasek KA, Huang S, Su YR, Sawyer DB, **Lenihan DJ**. Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis. *Amyloid*, 2016; 23(4):242-8. PMID 27809600
115. Brown SA, Sandhu N and **Lenihan DJ**, Dent S and Carver J. Response: Proposing and Meeting the Need for Interdisciplinary Cardio-Oncology Subspecialty Training. *J Card Fail*, 2016; 22(11):936.doi:10. 1016/j.cardfail.2016.09.018. PMID: 27663099
116. Zamorano JL, Lancellotti P, Rodrigues Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, **Lenihan DJ**, Lip GY, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM: Authors/Task Force Members.; 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity. Developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). ESC Committee for Practice Guidelines (CPG): *Eur Heart J*, 2016; 37(36):2768-801. PMID 27567406
117. Zamorano JL, Lancellotti P, Rodrigues Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, **Lenihan DJ**, Lip GY, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM: Authors/Task Force Members. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity. Developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). ESC Committee for Practice Guidelines (CPG): *Eur J Heart Fail*, 2017; 19(1):9-42.
118. **Lenihan DJ**, Anderson SA, Geisberg Lenneman C, Brittain E, Muldowney JAS, Mendes L, Zhao PZ, Iaci J, Frohwein S, Zolty R, Eisen A, Sawyer DB and Caggiano AO. A Phase I, single ascending dose study of cimaglermin α (Neuregulin 1 β 3) in patients with systolic dysfunction and heart failure. *JACC: Basic to Translational Science* 2016; 1(7):576-86.
119. Narayan HK, Wei W, Feng Z, **Lenihan D**, Plappert T, Englefield V, Fisch M, and Ky B. Cardiac mechanics and dysfunction with anthracyclines in the community: Results from the PREDICT study. *Open Heart*, 2017; 4(1):e000524.
120. Narayan V, Keefe S, Haas N, Wang L, Puzanov I, Putt M, Catino A, Fang J, Agarwal N, Hyman D, Smith AM, Finkelman BS, Narayan HK, Ewer S, ElAmm C, **Lenihan D** and Ky B. Prospective evaluation of sunitinib-induced cardiotoxicity in patients with metastatic renal cell carcinoma. *Clinical Cancer Res*, 2017; 23(14):3601-9.
121. Cox ZL, Lewis CM, Lai P, **Lenihan DJ**. Validation of an automated electronic algorithm and "dashboard" to identify and characterize decompensated heart failure admissions across a medical center. *Am Heart J*, 2017; 183:40-8. PMID 27979040
122. Armenian SH, Lacchetti C, **Lenihan D**. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary. *J Oncol Pract*, 2017; 13(4):270-5. JOP2016018770. PMID 2722796
123. **Lenihan DJ**. The horizon in cardio-oncology: "You are only as good as your endothelium". *J Am Coll Cardiol*, 2017; 70(2):163-4.
124. Ryzhov S, Matafonov A, Galindo CL, Zhang Q, Tran TL, **Lenihan DJ**, Lenneman CG, Feoktistov I, Sawyer DB. ERBB signaling attenuates proinflammatory activation of nonclassical monocytes. *Am J Physiol Heart Circ Physiol*, 2017; 312(5): H907-18.
125. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mayer EL, Moslehi J, Oeffinger K, Ray K, Ruddy K, **Lenihan D**. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*, 2017; 35(8): 893-911. PMID:27918725
126. Rubinstein S, Cornell RF, Du L, Concepcion B, Goodman S, Harrell S, Horst S., **Lenihan D**, Slosky D, Fogo A and Langone A. Novel pathologic scoring tools predict end-stage kidney disease in light chain (AL) amyloidosis. *Amyloid*, 2017; 24(3): 205-11.
127. Coutinho AD, Makenbaeva D, Farrelly E, Landsman-Blumberg PB and **Lenihan D**.

- Elevated cardiovascular disease risk in patients with chronic myelogenous leukemia seen in community-based oncology practices in the United States. *Clin Lymphoma Myeloma Leuk*, 2017; 17(10):676-83.
128. Miao J, Friedman E, Wu AHB, Todd JA, Estis J, Xu X, Nolan N, Bishop JJ and **Lenihan DJ**. Clinical utility of single molecule counting technology for quantification of KIM-1 in patients with heart failure and chronic kidney disease. *Clin Biochem*, 2017; 50(16-17): 889-95.
 129. **Lenihan D**. Cardio-oncology: What is the best practice we can all strive for? *Int J Cardiol*, 2017; 241:393-4.
 130. Oke O, Sethi T, Goodman S, Phillips S, Decker I, Rubinstein S, Concepcion B, Horst S, Jagasia M, Kassim A, Harrell SL, Langone A, **Lenihan D**, Rawling KT, Slosky D and Cornell RF. Outcomes from autologous hematopoietic cell transplantation versus chemotherapy alone for the management of light chain amyloidosis. *Biol Blood Marrow Transplant* 2017; 23(9):1473-7.
 131. Wells QS, Veatch OJ, Fessel JP, Joon AY, Levinson RT, Mosley JD, Held EP, Lindsay CS, Shaffer CM, Weeke PE, Glazer AM, Bersell KR, Van Driest SL, Karnes JH, Blair MA, Lagrone LW, Su YR, Bowton EA, Feng Z, Ky B, **Lenihan DJ**, Fisch MJ, Denny JC, Roden DM. Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults. *Pharmacogenet Genomics* 2017; 27(7):247-54.
 132. Cox ZL, Lai P, Lewis CM and **Lenihan DJ**. Centers for Medicare and Medicaid Services' readmission reports inaccurately describe an institution's decompensated heart failure admissions. *Clin Cardiol*, 2017; 40(9):620-5.
 133. Swiger KJ, Singh J and **Lenihan DJ**. Cardiomyopathic toxicity from chemotherapy: Is there an opportunity for preemptive intervention? *Curr Treat Options Cardiovasc Med*, 2017; 19(3):20.
 134. Decker I, Goodman SA, Phillips SE, **Lenihan DJ** and Cornell RF. The six-minute walk test is a valuable measure of functional change following chemotherapy for AL (light-chain) cardiac amyloidosis. *Br J Haematol* 2017; 177(3):481-3.
 135. **Lenihan DJ** and Sawyer DB. Cardio-oncology-A rapidly evolving and expanding field of medicine. *Heart Fail Clin*, 2017; 13(2):xiii.
 136. Ritts AJ, Cornell RF, Swiger K, Singh J, Goodman S and **Lenihan DJ**. Current concepts of cardiac amyloidosis: Diagnosis, clinical management, and the need for collaboration. *Heart Fail Clin*, 2017; 13(2):409-16.
 137. Fradley MG, Groarke JD, Laubach J, Alsina M, **Lenihan DJ**, Cornell RF, Maglio M, Shain KH, Richardson PG and Moslehi J. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. *Br J Haematol*, 2017; in press.
 138. Collins SP, Levy PD, Fermann GJ, Givertz MM, Martindale JM, Pang PS, Storrow AB, Diercks DD, Felker GM, Fonarow GC, Lanfear DJ, **Lenihan DJ**, Lindenfeld JM, Peacock F, Sawyer DM, Teerlink JM and Butler J. What's next for acute heart failure research? *Acad Emerg Med*, in press.
 139. Armstrong GT, Tolle JJ, Piana R, Santucci A, Leathers J, Ness KK, Mulrooney DA, Green DM, Joshi VM, Robinson LL, Hudson MM, **Lenihan D**. Exercise right heart catheterization for pulmonary hypertension identified on screening echocardiography in adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort. *Pediatr Blood Cancer*, 2017, in press.

Teaching Publications

1. **Lenihan DJ**, Yusuf SW. Acute Decompensated Heart Failure. *British Medical Journal*. E-Pub 2008.
2. **Lenihan DJ**, Yusuf SW. Myxomas. *British Medical Journal*. E-Pub 2008.
3. Ky, Bonnie and **Lenihan DJ**. Cancer Survivorship: Cardiac and Pulmonary Complications. Up to Date 2013.

Book Chapters

1. **Lenihan DJ**. Left Ventricular Diastolic Function. In: *Cardiac Nuclear Medicine*, 399-413, 1996.
2. **Lenihan DJ**. Selection of Non-Invasive Tests in the Emergency Room Settings and Coronary Care Unit. In: *Cardiac Nuclear Medicine*, 463-508, 1996.

3. **Lenihan DJ.** Nonpharmacologic Treatment of Heart Failure in the Elderly. In: *Geriatric Clinics*. 16:3, 477-487, 2000.
4. **Lenihan DJ.** Myocarditis. In: *Netters Cardiology*, 159-166, 2004.
5. **Lenihan DJ.** Diagnosis and Treatment of Heart Failure in the Cancer Patient. In: *Cancer and the Heart*, 2006.
6. Yeh ET, **Lenihan DJ**, Ewer M. The Diagnosis and Management of Cardiovascular Diseases in Cancer Patients. In: *Hurst's the Heart*. Ed(s) Valentin Fuster, 2008.
7. **Lenihan DJ.** Vascular Disease. In: *Medical Care of Cancer Patients*, Chapter 55; 2009.
8. **Lenihan DJ.** Myocarditis, *Netters Cardiology*, 2nd Edition, 2010.
9. **Lenihan DJ**, Wells QS. Chemotherapy Induced Cardiomyopathy. In: *Medical Management of Heart Failure*, 2013.
10. **Lenihan DJ.** Tumors Affecting the Cardiovascular System. In: *Braunwald's Heart Disease*. 10th edition 2013.
11. Sawyer, D and **Lenihan, DJ.** Managing Heart Failure in Cancer Patients. In: *Heart Failure: A Companion to Braunwald's Heart Disease*, 3rd edition.

Abstracts (past 6 years)

1. Michael S. Ewer, Thomas M. Suter, **Daniel J. Lenihan**, Liviu Niculescu, Aurora Breazna, George D. Demetri, Robert J. Motzer. Cardiovascular Events Among 1,090 Cancer Patients Treated with Sunitinib, Interferon, or Placebo: A Comprehensive Adjudicated Database Analysis. *European Society of Medical Oncology*, Milan. 2011.
2. Quinn Wells, **Daniel Lenihan**. Serum Vascular Endothelial Growth Factor and Platelet Derived Growth Factor Appear to Be Necessary for Human Coronary Collateralization. *American College of Cardiology 60th Annual Scientific Session*. New Orleans, Louisiana. 2011.
3. Carrie Geisberg, Connie Lewis, Jack Starmer, Zachary Cox, Thomas DiSalvo, Douglas Sawyer, **Daniel Lenihan**. Electronic Identifiers Accurately Identify Inpatient Heart Failure Admissions. *HFSA. Journal of Cardiac Failure*. 2011. Vol 17 No. 8S. pp S108:350.
4. Evan Brittain, **Daniel Lenihan**. Elevated Levels of Hepatocyte Growth Factor and Interleukin-6 Distinguish Cardiac Amyloid from Non-Ischemic Cardiomyopathy as a Cause of Heart Failure. *American Heart Association's Scientific Sessions 2011*. Orlando, FL.
5. Carrie Anna Geisberg, Connie Lewis, Jack Starmer, Rachel Garcia-Criswell, Thomas DiSalvo, Douglas B. Sawyer, **Daniel J. Lenihan**. Accuracy Of Inpatient Electronic Identification To Alert Disease Management Strategies In A Large Academic Medical Center. *Journal of The American College of Cardiology – JAMER COLL. CARDIOL*. 01/2011;57(14).
6. B.L. Cunningham, C.M. Lewis, Z. Cox, **D. Lenihan**. Newly designed heart failure education in a H2H demonstration project. *Heart & Lung – HEART LUNG*. 01/2011;40(4):376-377.
7. Michael S. Ewer, Thomas M. Suter, **Daniel J. Lenihan**, Liviu Niculescu, Aurora Breazna, George D. Demetri, Robert J. Motzer. Cardiovascular Events Among 1,090 Cancer Patients Treated with Sunitinib Interferon, or Placebo: A Comprehensive Adjudicated Database Analysis. *European Society of Medical Oncology*, Milan. 2011.
8. Geisberg C, Lewis, C, Starmer J, Garcia-Criswell R, DiSalvo T, Sawyer DB, **Lenihan D**. Accuracy of Inpatient Electronic Identification To Alert Disease Management Strategies In A Large Academic Medical Center. *JACC*, 2011;57(14) E1258.
9. A.K. Dickey, C.Geisberg, Y.R. Su, I.A. Mayer, J.A. Means-Powell, C. Silverstein, X. Peng, D. Freehardt, B. White, **D.J. Lenihan**, D. Sawyer. Strategies for protecting patients from anthracycline-induced cardiac dysfunction. *J Clin Oncol* 29: 2011 (suppl; abstr 591)
10. Tarek S Absi, Cristi L Galindo, Michael R Petracek, **Daniel J Lenihan**, Marzia Leacche, Douglas B Sawyer, John G Byrne, Jan Ru Su. Abstract 19023: Distinct Remodeling of Mitral Valve Leaflets in Severe Myxomatous and Ischemic Mitral Regurgitation. *Circulation*. 01/2012; 12;6(21 Supplement): A19023.
11. Nicole M Tricarico, Mary E. Davis, David Gailani, Holly C. Casanova, Shiu B. Leung, Nicholas Haglund, Simon Maltais, **Daniel Lenihan**. Factors Modifying Risk of Bleeding in Patients with Continuous Flow Left Ventricular Assist Devices. *ISHLT 2013*.
12. **Daniel J. Lenihan**, Sarah Anderson, Carrie Geisberg, Anthony Caggiano, Andrew Eisen, Evan Brittain, James A.S. Muldowney, III, Lisa Mendes, Douglas Sawyer. Safety and Tolerability of Glial Growth Factor

- 2 in Patients with Chronic Heart Failure: A Phase I Single Dose Escalation Study. American College of Cardiology 2013.
13. Zac Cox, Marion W. Calcutt, Thomas B. Morrison, Scott Akers, Mary E. Davis, **Daniel J. Lenihan**. Milrinone Plasma Concentrations across a Spectrum of Renal Function in Patients with Stage D Heart Failure. American College of Cardiology 2013.
14. Connie M. Lewis, Zachary Cox, Frank Papa, **Daniel J. Lenihan**. HF Positive Dashboard: Electronic Indicators Can Accurately Identify Inpatient Heart Failure Patients. Heart and Lung The Journal of Acute and Critical Care. 08/2014;43(4):375.
15. Nimanmah Bhatia, **Daniel J Lenihan**, Douglas B Sawyer, Carrie Geisberg Lenneman. Getting the SCOOP – Survey of Cardiovascular Outcomes from Oncology Patients During Survivorship. Journal of Cardiac Failure. 08/2014; 20(8S):S100.
16. Eitan A. Friedman, David C. Shisler, John A Todd, Joel Estis, Adnan Shah, Niamh Nolan, **Daniel J. Lenihan**. Endothelin-1 Is Independently Associated with the Annual Risk of Heart Failure Hospitalization. Journal of Cardiac Failure. 08/2014; 20(8S):S23.
17. Zachary Cox, Tom DiSalvo, Douglas B Sawyer, Connie M Lewis, **Daniel J Lenihan**. Take-CHARGE: Heart Failure Discharge Electronic Form for Admission Characterization and Quality Improvement. Journal of Cardiac Failure. 08/2014; 20(8S):S61.
18. Connie M. Lewis, Zachary Cox, **Daniel J. Lenihan**. Take-CHARGE: Heart Failure Discharge Checklist, Communication, and Data Collection Tool. Heart and Lung The Journal of Acute and Critical Care. 08/2014;43(4):373-4.
19. Friedman, E and **Lenihan, DJ**. Elevated Hepatocyte Growth Factor Is a Novel Specific Marker of Cardiac Amyloidosis. ACC 2015.
20. **Lenihan, DJ** et al. Sustained Improvement in Cardiac Function with Single Dose Cimaglermin Alfa (GGF2) in Human Left Ventricular Systolic Dysfunction. ACC 2015.
21. Eitan A. Friedman, Ugochukwu O. Egolum, David C. Shisler, [...] **Daniel J. Lenihan**. Journal of Cardiac Failure. Aug 2015.
22. **Connie M. Lewis**, Zachary Cox, Pikki Lai, **Daniel J. Lenihan**. Evaluation of Two Different Models to Predict Heart Failure Readmissions. Heart and Lung The Journal of Acute and Critical Care. July 2016.
23. Connie M. Lewis, Pikki Lai, Zacary Cox, **Daniel J. Lenihan**. Heart Failure Readmission Risk Prediction: Evaluation on Different Approaches for Patient Level Profiling Of Readmission. Journal of the American College of Cardiology. April 2016.
24. Oluchi Ukaegbu, Tarsheen Sethi, Stacey Goodman [...] Robert F. Cornell. Autologous Hematopoietic Cell Transplant (AHCT) Offers Prolonged Progression Free and Overall Survival in Patients with Light Chain Amyloidosis (AL) Compared with Chemotherapy Alone. March 2016.
25. Connie M. Lewis, Pikki Lai, Zacary Cox, [...] **Daniel J. Lenihan**. Young adults with heart failure: Who are they? What is their clinical profile? Heart and Lung The Journal of Acute and Critical Care. Nov 2015

PRESENTATIONS:

Invited Lectures

National and International Conferences

1. Heart Failure Management, 2001, University of North Carolina Chapel Hill, Amelia Island, FL, June 2001.
2. Heart Failure Management, 2002, University of North Carolina Chapel Hill, Amelia Island, FL, July 2002.
3. Heart Failure Management, 2003, University of North Carolina Chapel Hill, Amelia Island, FL, July 2003.
4. Recent Advances in Management of Pulmonary Hypertension, Current Trends in Cardiothoracic Anesthesia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, March 2005.
5. Optimal Medical Management of CHF in 2005, Concepts in Contemporary Cardiology, Houston, TX, April 2005.
6. Established Therapy and New Frontiers, Heart Failure Management 2005, University of North Carolina Chapel Hill, Amelia Island, FL, July 2005.
7. Prevention and Treatment of Cardiovascular Complications in the Oncology Patient, The 27th Annual Pharmacy Symposium on Cancer Chemotherapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, November 2005.
8. Cardiac Emergencies in Cancer Patients, Oncologic Emergencies, The University of Texas M.D. Anderson Cancer Center, Houston, TX, January 2006.
9. Epidemiology and Prevention of Diastolic Heart Failure, Preventive Cardiology Forum XVI, The University of Texas Health Science Center at Houston, Houston, TX, February 2006.
10. Multidisciplinary Approach to CVD in the Cancer Patient, CONQUER: Cancer and Cardiovascular

- Disease: Increasing the Success of Chemotherapy by Reducing CVD as a Barrier and Long-term Risk, Houston, TX, October 2006.
11. Epidemiology of Cancer and Heart Disease, American College of Cardiology 56th Annual Scientific Session, American College of Cardiology, New Orleans, LA, March 2007.
 12. Guidelines for Chemotherapy-Related Cardiac Toxicity, Heart Failure Society of America 2007, Washington, DC, September 2007.
 13. Chemotherapy Induced Heart Failure: Do we have any guidelines?, HFSA 8th Annual Scientific Session, Heart Failure Society of America, Toronto, Canada, September 2008.
 14. Heart Failure Patients Receiving Anti-Cancer Therapy: Updates and Issues of Evaluation, Heart Failure Society of America 2008, Toronto, Ontario, Canada, September 2008.
 15. Cardiotoxicity Associated with Chemotherapy, Heart Failure Society of America 2011, Boston, MA, September 2011.
 16. How Cardiotoxicity with Cancer Therapy can lead to Promising Heart Failure Treatment: The Story of Neuregulin, Ground Rounds, Milan Italy, March 2012.
 17. Cardiotoxicity of Cancer Chemotherapeutic Agents: The Extent and Magnitude of Problem and Clinical Evidence, American College of Cardiology 61st Annual Scientific Session, Chicago, IL, March 2012.
 18. Early Detection, Prevention and Management of Cardiac Disease During Cancer Therapy, World Pharma Congress, Philadelphia, PA, June 2012.
 19. Oncology Medications: State-of-the-art Identification and Management of Potential CV Safety Issues During Development [Overview of Myocardial Cardiotoxicity Assessment During Development], DIA 2012 48th Annual Meeting, Philadelphia, PA, June 2012.
 20. PREDICT Study, Second International Conference on Cancer and the Heart, The University of Texas MD Anderson Cancer Center, Houston, TX, November 2012.
 21. Cardiac Safety During Chemotherapy: The Scope of the Problem, American Heart Association Scientific Sessions 2012, Los Angeles, CA, November 2012.
 22. ACC Washington DC, 2013. "Clinically Practical Use of Cardiac Biomarkers in Cancer Patients"
 23. ASCO "Cardiac Dysfunction in Cancer Patients", Chicago, IL, 2014.
 24. HFSA, Las Vegas, NV 2014 "Cardiotoxicity".
 25. ACC, San Diego, CA, 2015. Cardio-Oncology Intensive.
 26. British Cardiac Society. Cardiac biomarkers during cancer therapy, Manchester, England, 2015.
 27. World Congress on Angiogenesis, Boston, MA, April 2015.
 28. Cardiac Issues in Survivorship, ASCO Meeting, San Francisco, CA, Jan 2016.
 29. Anthracycline Induced Cardiomyopathy, ACC Meeting, Chicago, IL 2016.
 30. Cardiac Safety During Chemotherapy, ASCO, Chicago, IL 2016.

Other, Seminar Invitations and Scientific Exhibitions

1. Established Therapy and New Frontiers, Heart Failure Management 2004, University of North Carolina Chapel Hill, Amelia Island, FL, July 2004.
2. Critical Care, Critical Care Fellowship Workshop Series, The University of Texas Health Science Center at Houston, Houston, TX, November 2005.
3. Heart Failure, Cardiology Fellowship Lecture Series, The University of Texas Medical School at Houston, Cardiology, Houston, TX, January 2006.
4. Early Detection of Cardiotoxicity and Optimal Therapy, Cancer Grand Rounds, Memorial Sloan-Kettering Cancer Center, Cardiology, New York, NY, January 2007.
5. Trinity University, Student Address – Journal Club and public seminar, San Antonio, TX, October 2014
6. Indiana University Grand Rounds, Indianapolis, IN, October 2014.
7. New York State ACC Annual Scientific Meeting, Presentation on Cardio-Oncology, Albany, NY, October 2014.
8. Cardiac Safety during bone marrow transplantation, 2015 BMT Tandem Meeting, February 2015.